Alnylam Pharmaceuticals Inc (ALNY):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Alnylam Pharmaceuticals Inc (ALNY) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7398
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late stage product candidates include Patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis, Inclisiran for hypercholesterolemia, Fitusiran for hemophilia and rare bleeding disorders and Givosiran for acute hepatic porphyrias. It operates subsidiaries in the US, Canada, France, Germany, Italy, Spain, Sweden, the Netherlands, Switzerland and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc (ALNY) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Alnylam Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Alnylam Pharmaceuticals Inc, Medical Equipment, Deal Details 11
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 11
Equity Offering 12
Alnylam Pharma Raises USD805 Million in Public Offering of Shares 12
Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 14
Alnylam Pharma Raises USD518 Million in Public Offering of Shares 16
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 18
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 19
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 20
Alnylam Pharmaceuticals Inc – Key Competitors 22
Alnylam Pharmaceuticals Inc – Key Employees 23
Alnylam Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Joint Venture 25
Recent Developments 26
Financial Announcements 26
Aug 02, 2018: Alnylam Pharmaceuticals reports second quarter 2018 financial results and highlights recent period activity 26
May 03, 2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity 30
Feb 08, 2018: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity 33
Aug 09, 2017: Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity 36
May 05, 2017: Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity 38
Feb 08, 2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity 40
Corporate Communications 43
Oct 10, 2018: Alnylam appoints Dr. Margaret Hamburg to Board of Directors 43
Jun 20, 2018: Alnylam Pharmaceuticals Announces Senior Management Changes 44
May 15, 2018: Alnylam Appoints Colleen Reitan to the Board of Directors 45
Jun 19, 2017: Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term 46
May 09, 2017: Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders 47
Jan 03, 2017: Alnylam Announces Management Change and Key Promotion 49
Legal and Regulatory 50
Oct 03, 2018: Kessler Topaz Meltzer & Check: securities fraud class action filed Against Alnylam Pharmaceuticals 50
Apr 20, 2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam 51
Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 52
Product News 53
Oct 11, 2018: US Patent Trial & Appeal Board (PTAB) Upholds Silence Patent by Denying First of Five Patent Grant Review Applications Filed by Alnylam 53
Jun 12, 2017: Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Alnylam Pharmaceuticals Inc, Medical Equipment, Key Facts, 2017 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Alnylam Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Alnylam Pharmaceuticals Inc, Deals By Market, 2012 to YTD 2018 9
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 11
Alnylam Pharma Raises USD805 Million in Public Offering of Shares 12
Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 14
Alnylam Pharma Raises USD518 Million in Public Offering of Shares 16
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 18
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 19
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 20
Alnylam Pharmaceuticals Inc, Key Competitors 22
Alnylam Pharmaceuticals Inc, Key Employees 23
Alnylam Pharmaceuticals Inc, Subsidiaries 24
Alnylam Pharmaceuticals Inc, Joint Venture 25

List of Figures
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Alnylam Pharmaceuticals Inc (ALNY):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Valeura Energy Inc (VLE):石油・ガス:M&Aディール及び事業提携情報
    Summary Valeura Energy Inc (Valeura) is an upstream oil and gas company that explores for, develops and produces oil and natural gas. It operates mainly in the Thrace Basin in the northwest of Turkey pursuing conventional shallow natural gas, unconventional tight gas and a basin-centered gas accumul …
  • Thomas Cook Group plc (TCG):企業の財務・戦略的SWOT分析
    Thomas Cook Group plc (TCG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Guerbet SA (GBT)-医療機器分野:企業M&A・提携分析
    Summary Guerbet SA (Guerbet) is a specialty pharmaceutical company which manufactures and markets medical imaging contrast agents destined for diagnostic purposes. The company provides a wide range of contrast agents for X-ray examinations and Magnetic Resonance Imaging (MRI). Guerbet also provides …
  • Litgrid AB (LGD1L):企業の財務・戦略的SWOT分析
    Litgrid AB (LGD1L) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Korean Reinsurance Company:企業の戦略・SWOT・財務情報
    Korean Reinsurance Company - Strategy, SWOT and Corporate Finance Report Summary Korean Reinsurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Owens & Minor, Inc.:企業の戦略・SWOT・財務情報
    Owens & Minor, Inc. - Strategy, SWOT and Corporate Finance Report Summary Owens & Minor, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • P.F. Chang’s China Bistro Inc:企業の戦略・SWOT・財務分析
    P.F. Chang's China Bistro Inc - Strategy, SWOT and Corporate Finance Report Summary P.F. Chang's China Bistro Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Aslan Pharmaceuticals Pte Ltd (6497):製薬・医療:M&Aディール及び事業提携情報
    Summary Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd, is a biotechnology company that offers immuno-oncology agents and targeted therapies. The company’s pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhib …
  • Metabolon Inc-医療機器分野:企業M&A・提携分析
    Summary Metabolon Inc (Metabolon) is a health technology company that develops clinical diagnostic tests for healthcare markets. The company’s products include non-alcoholic steatohepatitis test, GFR test, quantose IGT test, prostarix and prostarix plus tests, among others. Its quantose IR test is a …
  • Eagle Pharmaceuticals Inc (EGRX):企業の財務・戦略的SWOT分析
    Eagle Pharmaceuticals Inc (EGRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Seven West Media Limited:企業のM&A・事業提携・投資動向
    Seven West Media Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Seven West Media Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Finsbury Food Group PLC (FIF):企業の財務・戦略的SWOT分析
    Summary Finsbury Food Group PLC (Finsbury) is a manufacturer and supplier of bakery products. The company offers cake products such as party cakes, seasonal and festive cakes; premium cakes, kids' cakes, triple-layer cakes, loaf cakes, crumble cakes, tiffin, mini and giant rolls, roulades, rocky roa …
  • ON Semiconductor Corp (ON):企業の財務・戦略的SWOT分析
    ON Semiconductor Corp (ON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Technicolor SA:企業の戦略・SWOT・財務情報
    Technicolor SA - Strategy, SWOT and Corporate Finance Report Summary Technicolor SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Asian Infrastructure Investment Bank:電力:M&Aディール及び事業提携情報
    Summary Asian Infrastructure Investment Bank (AIIB) is a multilateral financial institution. The company develops infrastructure and other productive sectors. It provides sovereign and non-sovereign finance for sustainable projects in energy and power, transportation and telecommunications, rural in …
  • SpectraScience Inc (SCIE)-医療機器分野:企業M&A・提携分析
    Summary SpectraScience Inc (SpectraScience) is a medical device company, which undertakes the design, development, manufacture and marketing of light-based technology products. The company offers its proprietary WavSTAT Optical Biopsy System to diagnose tissue health optically by using light. This s …
  • RattanIndia Power Ltd (RTNPOWER):企業の財務・戦略的SWOT分析
    RattanIndia Power Ltd (RTNPOWER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Kolltan Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Kolltan Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kolltan Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • XALT Energy LLC:企業の戦略的SWOT分析
    XALT Energy LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆